Skip to content
  • Clinical Studies
  • Pharma SOP’s
  • Pharma tips
  • Pharma Books
  • Stability Studies
  • Schedule M

Pharma GMP

Your Gateway to GMP Compliance and Pharmaceutical Excellence

  • Home
  • Quick Guide
  • GMP Failures & Pharma Compliance
    • Common GMP Failures
    • GMP Documentation & Records Failures
    • Cleaning & Sanitation Failures in GMP Audits
    • HVAC, Environmental Monitoring & Cross-Contamination Risks
  • Toggle search form

Designing SOPs for Cleaning Non-Product Contact Areas

Posted on November 25, 2025November 24, 2025 By digi


Designing SOPs for Cleaning Non-Product Contact Areas: A Step-by-Step GMP Tutorial

Step-by-Step Guidance on Designing SOPs for Cleaning Non-Product Contact Areas in Pharmaceutical GMP Facilities

Effective contamination control is a cornerstone of Good Manufacturing Practice (GMP) compliance, ensuring patient safety and product quality. While significant attention is often given to cleaning procedures for product contact surfaces, non-product contact areas within pharmaceutical facilities also require methodical cleaning to prevent cross-contamination, microbial proliferation, and environmental integrity breaches. This tutorial provides a detailed, step-by-step framework for sop design focused on establishing a robust cleaning checklist for non product contact areas, incorporating defined responsibilities, cleaning frequency, and regulatory expectations pertinent to US, UK, and EU GMP environments.

Step 1: Defining the Scope and Objectives of the SOP for Non-Product Contact Areas

The first step in developing an SOP for cleaning non-product contact areas is to articulate its scope and objectives clearly. These areas typically include corridors, change rooms, equipment exteriors, floors, walls, ceilings, drains, ventilation grills, lighting fixtures, and storage zones that do not directly touch the product but can serve as contamination sources.

Why is defining scope essential? It ensures that all relevant facility locations are systematically covered without ambiguity. It also clarifies the applicability of cleaning activities for personnel executing the procedures.

  • Identify all non-product contact areas: Collaborate with facility engineering and QA to map and classify these into risk zones, considering proximity to manufacturing lines and cleanroom classifications.
  • Set contamination control objectives: Objectives may include removing dust, particulates, microbial load, and residues that might compromise controlled environments.
  • Align with relevant GMP regulations and guidelines: For instance, EU GMP Annex 1 mandates contamination control in classified cleanrooms and associated areas, while FDA 21 CFR Part 211 emphasizes cleaning adequacy for entire facilities.
Also Read:  Audit Comments on Poor Cleaning of Non-Product Areas

At this stage, determine the regulatory framework most relevant to your facility. For example, facilities operating under EMA guidance will reference EU GMP Volume 4, whereas US sites emphasize FDA GMPs. PIC/S and WHO GMP texts provide harmonized expectations that can inform SOP structure globally.

Step 2: Developing a Comprehensive Cleaning Checklist for Non-Product Contact Areas

With the scope established, the next critical component is designing a detailed and practical cleaning checklist for non product contact areas. The checklist serves as a day-to-day operational tool guiding cleaning personnel through standardized activities to maintain environmental cleanliness consistently.

Key considerations for checklist development include:

  • Segmentation by area and surface type: The checklist should be structured by zones (e.g., hallways, changing rooms, equipment exteriors) with specific items such as floor types, wall panels, HVAC grilles, or light fixtures indicated.
  • Cleaning methods and agents: Each item should specify appropriate cleaning techniques (e.g., wet wiping, mopping, HEPA vacuuming) and validated disinfectants or detergents suitable for the surfaces involved.
  • Risk-based cleaning frequency: Define cleaning cycles based on potential contamination risks and traffic flow. High-risk adjacent areas to manufacturing suites may require multiple cleanings daily, whereas low-traffic storage zones might be cleaned weekly.
  • Verification and quality checks: The checklist should include space for documenting completion, inspector initials, and verification dates to establish traceability and accountability.

Structuring this checklist in tabular format ensures clarity, usability, and ease of audit review. A simplified example for corridor cleaning might read:

Area Cleaning Task Method Cleaning Agent Frequency Responsible Person Comments/Verification
Main Corridor Floor Mop and disinfect floor Wet mop connection with microfiber mop Quaternary ammonium disinfectant Twice daily (start/end shifts) Cleaning Staff Initials and date
Equipment Exterior Wipe with disinfectant Manual wiping 70% Isopropanol Daily after manufacturing Manufacturing Operator Initials and date

Incorporating a risk assessment approach whenever possible aligns this checklist with ICH Q9 Quality Risk Management principles, allowing customization to the facility’s unique risk profile.

Step 3: Defining Roles and Responsibilities in the Cleaning SOP Design

Clarity on responsibilities is paramount in SOP design to establish ownership and accountability during cleaning execution, supervision, and documentation. This section should uniformly define roles from operational personnel to supervisory and quality oversight departments.

Also Read:  Calibration and Maintenance Program for QC Laboratory Instruments

Key elements include:

  • Cleaning Personnel: Responsible for executing cleaning tasks as per checklist, using approved cleaning agents and methods, and accurately documenting completion.
  • Area Supervisors or Shift Leaders: Tasked with daily oversight, ensuring compliance with schedules and proper technique, and addressing non-conformities promptly.
  • Quality Assurance (QA): Provides review and approval of cleaning SOPs and checklists, conducts periodic audits on procedure execution, and manages training requirements.
  • Validation and Microbiology Departments: Support qualification of cleaning agents, methods, and verify microbial contamination control efficacy periodically.

The SOP should distinctly communicate escalation protocols for deviations encountered during cleaning, such as ineffective disinfection or damage to facilities, requiring QA intervention. It is also advisable to include training requirements for all involved personnel to ensure method and hygiene competency.

For illustration, the typical responsibility matrix may be summarized as:

  • Cleaning Staff: Perform cleaning and fill checklist.
  • Supervisors: Review completed checklists daily.
  • QA: Audit compliance monthly and approve SOP revisions.

The clarity of responsibilities supports compliance with FDA expectations concerning adequate personnel training and process ownership, as outlined under 21 CFR Part 211 Subpart B – Personnel.

Step 4: Establishing Cleaning Frequencies Aligned with GMP Compliance

Determining appropriate cleaning frequency is critical to maintaining facility cleanliness without unnecessary resource expenditure. Frequency decisions must consider contamination risk, usage patterns, regulatory standards, and environmental monitoring results.

General principles for frequency setting in non-product contact areas are as follows:

  • High-Risk Adjacent Areas: Include corridors directly outside cleanrooms and gowning areas. Cleaning is typically required at least twice daily with additional cleaning after spills or visible contamination.
  • Medium-Risk Zones: Ancillary rooms with moderate personnel traffic might be cleaned daily or several times per week.
  • Low-Risk Locations: Offices, storage rooms, and mechanical rooms can be cleaned weekly or monthly, provided environmental controls are adequate.

Contextualizing frequency with environmental monitoring data (particle counts, microbial load) is recommended to justify and adjust cleaning schedules. This data-driven approach aligns with the ongoing revision philosophy of GMP documents such as FDA’s Guidelines on Sterile Drug Products.

Also Read:  Audit Findings on Poor Control of Material Dispensing Operations

SOPs should also detail reactive cleaning frequencies, such as immediate cleaning following contamination events or equipment breakdowns. Procedures for increasing cleaning frequency during high production periods or outbreak situations, such as pandemics, must be addressed explicitly.

Step 5: Review, Training, and Continual Improvement of the Cleaning SOP

Developing an effective SOP for cleaning non-product contact areas does not end at writing; it requires an iterative process of review, training, and continuous improvement to ensure sustained compliance and effectiveness.

Recommended actions include:

  • Periodic Review: Implement a scheduled SOP review, typically annually or upon significant process changes, to incorporate regulatory updates, new cleaning technologies, or identified compliance gaps.
  • Training Programs: Develop comprehensive training curricula tailored to the SOP content for all involved personnel. Training should document understanding of cleaning techniques, product safety risks, and documentation requirements. Refresher training frequency should also be established.
  • Audit and Inspection Feedback: Routinely audit cleaning execution and documentation, addressing any deviations with root cause analysis and corrective/preventive actions (CAPA). Incorporate feedback from regulatory inspections to align with interpretations of guidances such as PIC/S PE 009-15.
  • Use of Technology: Consider electronic batch records or tablet-based checklists to improve documentation reliability and ease of review.

Maintaining documentary control as per EU GMP Volume 4 Annex 15 supports data integrity and traceability, vital for audits and inspections. Moreover, a robust CAPA cycle ensures that the SOP evolves to meet operational challenges and regulatory expectations continuously.

Conclusion

Designing a comprehensive SOP for cleaning non-product contact areas is an integral component of pharmaceutical GMP compliance. A well-constructed cleaning checklist for non product contact areas ensures methodical cleaning, clarity in responsibilities, and appropriate frequency aligned with facility risk profiles and regulatory requirements.

By following the five-step approach outlined—defining scope, developing checklists, assigning responsibilities, setting frequencies, and fostering continual improvement—pharmaceutical manufacturers can maintain optimal environment control, support product quality, and withstand rigorous inspection scrutiny across US, UK, and EU jurisdictions.

Non-Product Areas Tags:cleaning, non product areas, pharmagmp, sop

Post navigation

Previous Post: Audit Comments on Poor Cleaning of Non-Product Areas
Next Post: Why Non-Product Contact Area Cleaning Still Matters for GMP Compliance

Quick Guide

  • GMP Basics
    • Introduction to GMP
    • What is cGMP?
    • Key Principles of GMP
    • Benefits of GMP in Pharmaceuticals
    • GMP vs. GxP (Good Practices)
  • Regulatory Agencies & Guidelines
    • WHO GMP Guidelines
    • FDA GMP Guidelines
    • MHRA GMP Guidelines
    • SCHEDULE – M – Revised
    • TGA GMP Guidelines
    • Health Canada GMP Regulations
    • NMPA GMP Guidelines
    • PMDA GMP Guidelines
    • EMA GMP Guidelines
  • GMP Compliance & Audits
    • How to Achieve GMP Certification
    • GMP Auditing Process
    • Preparing for GMP Inspections
    • Common GMP Violations
    • Role of Quality Assurance
  • Quality Management Systems (QMS)
    • Building a Pharmaceutical QMS
    • Implementing QMS in Pharma Manufacturing
    • CAPA (Corrective and Preventive Actions) for GMP
    • QMS Software for Pharma
    • Importance of Documentation in QMS
    • Integrating GMP with QMS
  • Pharmaceutical Manufacturing
    • GMP in Drug Manufacturing
    • GMP for Biopharmaceuticals
    • GMP for Sterile Products
    • GMP for Packaging and Labeling
    • Equipment and Facility Requirements under GMP
    • Validation and Qualification Processes in GMP
  • GMP Best Practices
    • Total Quality Management (TQM) in GMP
    • Continuous Improvement in GMP
    • Preventing Cross-Contamination in Pharma
    • GMP in Supply Chain Management
    • Lean Manufacturing and GMP
    • Risk Management in GMP
  • Regulatory Compliance in Different Regions
    • GMP in North America (FDA, Health Canada)
    • GMP in Europe (EMA, MHRA)
    • GMP in Asia (PMDA, NMPA, KFDA)
    • GMP in Emerging Markets (GCC, Latin America, Africa)
    • GMP in India
  • GMP for Small & Medium Pharma Companies
    • Implementing GMP in Small Pharma Businesses
    • Challenges in GMP Compliance for SMEs
    • Cost-effective GMP Compliance Solutions for Small Pharma Companies
  • GMP in Clinical Trials
    • GMP Compliance for Clinical Trials
    • Role of GMP in Drug Development
    • GMP for Investigational Medicinal Products (IMPs)
  • International GMP Inspection Standards and Harmonization
    • Global GMP Inspection Frameworks
    • WHO Prequalification and Inspection Systems
    • US FDA GMP Inspection Programs
    • EMA and EU GMP Inspection Practices
    • PIC/S Role in Harmonized Inspections
    • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)
  • GMP Blog

Latest Posts

  • GMP-cGMP Regulations & Global Standards
    • FDA cGMP Regulations for Drugs & Biologics
    • cGMP Requirements for Pharmaceutical Manufacturers
    • ICH Q7 and API GMP Expectations
    • Global & ISO-Based GMP Standards
    • GMP for Medical Devices & Combination Products
    • GMP for Pharmacies & Hospital Pharmacy Settings
  • Applied GMP in Pharma Manufacturing & Operations
    • GMP for Pharmaceutical Drug Product Manufacturing
    • GMP for Biotech & Biologics Manufacturing
    • GMP Documentation
    • GMP Compliance
    • GMP for APIs & Bulk Drugs
    • GMP Training
  • Computer System Validation (CSV) & GxP Computerized Systems
    • CSV Fundamentals in Pharma & Biotech
    • FDA CSV Guidance & 21 CFR Part 11 Alignment
    • GAMP 5 & Risk-Based Validation Approaches
    • CSV in Pharmaceutical & GxP Industries (Use-Cases & System Types)
    • CSV Documentation
    • CSV for Regulated Equipment & Embedded Systems
  • Data Integrity & 21 CFR Part 11 Compliance
    • Data Integrity Principles in cGMP Environments
    • FDA Data Integrity Guidance & Expectations
    • 21 CFR Part 11 – Electronic Records & Signatures
    • Data Integrity in GxP Computerized Systems
    • Data Integrity Audits
  • Pharma GMP & Good Manufacturing Practice
    • FDA 483, Warning Letters & GMP Inspections
    • Data Integrity, ALCOA+ & Part 11 / Annex 11
    • Process Validation, CPV & Cleaning Validation
    • Contamination Control & Annex 1
    • PQS / QMS / Deviations / CAPA / OOS–OOT
    • Documentation, Batch Records & GDP
    • Sterility, Microbiology & Utilities
    • CSV, GAMP 5 & Automation
    • Dosage-Form–Specific GMP (Solids, Liquids, Sterile, Topicals)
    • Supply Chain, Warehousing, Cold Chain & GDP
Widget Image
  • Never Assign Batch Release Responsibilities to Non-QA Personnel in GMP

    Never Assign Batch Release Responsibilities… Read more

  • Manufacturing & Batch Control
    • GMP manufacturing process control
    • Batch Manufacturing record requirements
    • Master Batch record template for pharmaceuticals
    • In Process control checks in tablet manufacturing
    • Line clearance procedure before batch start
    • Batch reconciliation in pharmaceutical manufacturing
    • Yield reconciliation GMP guidelines
    • Segregation of different strength products GMP
    • GMP controls for high potency products
    • Cross Contamination prevention in manufacturing
    • Line clearance checklist for production
    • Batch documentation review before qa release
    • Process parameters control limits in pharma
    • Equipment changeover procedure GMP
    • Batch manufacturing deviation handling
    • GMP expectations for batch release
    • In Process sampling plan for tablets
    • Visual inspection of dosage forms GMP requirements
    • In Process checks for filled vials
    • Startup and Shutdown procedure for manufacturing line
    • GMP requirements for blending and mixing operations
    • Process Control strategy in pharmaceutical manufacturing
    • Uniformity of dosage units in process controls
    • GMP checklist for oral solid dosage manufacturing
    • Process Control
    • Batch Documentation
    • Master Batch Records
    • In-Process Controls
    • Line Clearance
    • Yield & Reconciliation
    • Segregation & Mix-Ups
    • High Potency Products
    • Cross Contamination Control
    • Line Clearance
    • Batch Review
    • Process Parameters
    • Equipment Changeover
    • Deviations
    • Batch Release
    • In-Process Sampling
    • Visual Inspection
    • In-Process Checks for Vials
    • Start-Up & Shutdown
    • Blending & Mixing
    • Control Strategy
    • Dosage Uniformity
    • Hold Time Studies
    • OSD GMP Checklist
  • Cleaning & Contamination Control
  • Warehouse & Material Handling
    • Warehouse GMP
    • Material Receipt
    • Sampling
    • Status Labelling
    • Storage Conditions
    • Rejected & Returned
    • Reconciliation
    • Controlled Drugs
    • Dispensing
    • FIFO & FEFO
    • Cold Chain
    • Segregation
    • Pest Control
    • Env Monitoring
    • Palletization
    • Damaged Containers
    • Stock Verification
    • Sampling & Weighing Areas
    • Issue to Production
    • Traceability
    • Printed Materials
    • Intermediates
    • Cleaning & Housekeeping
    • Status Tags
    • Warehouse Audit
  • QC Laboratory & Testing
    • Analytical Method Validation
    • Chromatography Systems
    • Dissolution Testing
    • Assay & CU
    • Impurity Profiling
    • Stability & QC
    • OOS Investigations
    • OOT Trending
    • Sample Management
    • Reference Standards
    • Equipment Calibration
    • Instrument Qualification
    • LIMS & Electronic Data
    • Data Integrity
    • Microbiology QC
    • Sterility & Endotoxin
    • Environmental Monitoring
    • QC Documentation
    • Results Review
    • Method Transfer
    • Forced Degradation
    • Compendial Methods
    • Cleaning Verification
    • QC Deviations & CAPA
    • QC Lab Audits
  • Manufacturing & In-Process Control
    • Batch Manufacturing Records
    • Batch Manufacturing Records
    • Line Clearance
    • In-Process Sampling & Testing
    • Yield & Reconciliation
    • Granulation Controls
    • Blending & Mixing
    • Tablet Compression Controls
    • Capsule Filling Controls
    • Coating Process Controls
    • Sterile & Aseptic Processing
    • Filtration & Sterile Filtration
    • Visual Inspection of Parenteral
    • Packaging & Labelling Controls
    • Rework & Reprocessing
    • Hold Time for Bulk & Intermediates
    • Manufacturing Deviations & CAPA
  • Documentation, Training & QMS
    • SOP & Documentation Control
    • Training & Competency Management
    • Change Control & QMS Lifecycle
    • Internal Audits & Self-Inspection
    • Quality Metrics, Risk & Management Review
  • Production SOPs
  • QC Laboratory SOPs
    • Sample Management
    • Analytical Methods
    • HPLC & Chromatography
    • OOS & OOT
    • Data Integrity
    • Documentation
    • Equipment
  • Warehouse & Materials SOPs
    • Material Receipt
    • Sampling
    • Storage
    • Dispensing
    • Rejected & Returned
    • Cold Chain
    • Stock Control
    • Printed Materials
    • Pest & Housekeeping
  • Cleaning & Sanitization SOPs
  • Equipment & Qualification SOPs
  • Documentation & Data Integrity SOPs
  • Deviation/OOS/CAPA SOPs
    • Deviation Management
    • Root Cause
    • CAPA
    • OOS/OOT
    • Complaints
    • Recall
  • Training & Competency SOPs
    • Training System
    • Role-Based Training
    • OJT
    • Refresher Training
    • Competency
  • QA & QMS Governance SOPs
    • Quality Manual
    • Management Review
    • Internal Audit
    • Risk Management
    • Vendors & Outsourcing
  • About Us
  • Privacy Policy & Disclaimer
  • Contact Us

Copyright © 2025 Pharma GMP.

Powered by PressBook WordPress theme